



DISCOID LUPUS ERYTHEMATOSUS

RMA ID Number	Reference List for RMA400-2 as at April 2025
---------------	--

74508	Adachi A, Nagai H, Horikawa T (2007). Anti-SSA/Ro antibody as a risk factor for fluorouracil-induced drug eruptions showing acral erythema and discoid-lupus-erythematosus-like lesions. <i>Dermatology</i> , 214(1): 85-8.
119744	Adrichem ME, Starink MV, van Leeuwen EM, et al (2017). Drug-induced cutaneous lupus erythematosus after immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a case series. <i>J Peripher Nerv Syst</i> , 22(3): 213-8.
119753	Al-Jefri K, Newbury-Birch D, Muirhead CR, et al (2017). High prevalence of alcohol use disorders in patients with inflammatory skin diseases. <i>Br J Dermatol</i> , 177(3): 837-44.
119249	Allali S, Chasset F, Kirova Y, et al (2022). Unusual severe radiation-induced toxicity in a patient with discoid lupus erythematosus: A case report and critical review of the literature. <i>Cancer Radiother</i> , 26(4): 594-8.
1163	Arevalo-Bermudez MD, Paradela S, Balboa-Barreiro V, et al (2020). Cutaneous lupus erythematosus: factors related to cutaneous activity and damage in a cohort of 260 patients from A Coruna, Spain. <i>Lupus</i> , 29(9): 1021-30.
122063	Ashraf E, Ghouse AN, Siddiqui S, et al (2020). Discoid lupus erythematosus: a cross-sectional study from the Sindh Institute of Skin Diseases, Karachi, Pakistan. <i>Cureus</i> , 12(10): e11201.
120277	Australian Medicines Handbook (2024). Capecitabine. Retrieved 19 August 2024, from https://amhonline.amh.net.au/chapters/anticancer-drugs/antimetabolites/capecitabine
120280	Australian Medicines Handbook (2024). Combined oral contraceptives. Retrieved 19 August 2024, from https://amhonline.amh.net.au/chapters/obstetric-gynaecological-drugs/drugs-contraception/combined-oral-contraceptives
122103	Australian Medicines Handbook (2024). Drugs for contraception. Retrieved 19 July 2024, from https://amhonline.amh.net.au/chapters/obstetric-gynaecological-drugs/drugs-contraception/contraception?menu=vertical
122088	Australian Medicines Handbook (2024). Fluorouracil (skin). Retrieved 19 July 2024, from https://amhonline.amh.net.au/chapters/dermatological-drugs/drugs-actinic-keratoses/fluorouracil-skin
122089	Australian Medicines Handbook (2024). Fluorouracil. Retrieved 19 July 2024, from https://amhonline.amh.net.au/chapters/anticancer-drugs/antimetabolites/fluorouracil?menu=vertical
122102	Australian Medicines Handbook (2024). Hormone replacement therapy. Retrieved 19 July 2024, from https://amhonline.amh.net.au/chapters/obstetric-gynaecological-drugs/drugs-menopausal-symptoms/hormone-replacement-therapy?menu=vertical

122090	Australian Medicines Handbook (2024). Leflunomide. Retrieved 19 July 2024, from https://amhonline.amh.net.au/chapters/immunomodulators-anti-inflammatories/other-immunomodulators/leflunomide
122091	Australian Medicines Handbook (2024). Nivolumab. Retrieved 20 July 2024, from https://amhonline.amh.net.au/chapters/anticancer-drugs/anticancer-antibodies/nivolumab
122092	Australian Medicines Handbook (2024). Normal immunoglobulin. Retrieved 19 July 2024, from https://amhonline.amh.net.au/appendices/appendix-additional-drugs/immunoglobulins/normal-immunoglobulin
122098	Australian Medicines Handbook (2024). Palbociclib. Retrieved 19 July 2024, from https://amhonline.amh.net.au/chapters/anticancer-drugs/kinase-inhibitors/palbociclib
122099	Australian Medicines Handbook (2024). Pembrolizumab. Retrieved 19 July 2024, from https://amhonline.amh.net.au/chapters/anticancer-drugs/anticancer-antibodies/pembrolizumab
122105	Australian Medicines Handbook (2024). Progestogens. Retrieved 19 July 2024, from https://amhonline.amh.net.au/chapters/obstetric-gynaecological-drugs/drugs-contraception/progestogens?menu=vertical
122100	Australian Medicines Handbook (2024). Secukinumab. Retrieved 19 July 2024, from https://amhonline.amh.net.au/chapters/dermatological-drugs/drugs-psoriasis/immunosuppressants-dermatology/secukinumab
122101	Australian Medicines Handbook (2024). TNF-alpha antagonists. Retrieved 19 July 2024, from https://amhonline.amh.net.au/chapters/immunomodulators-anti-inflammatories/tnf-alpha-antagonists?menu=vertical
74381	Bae YI, Yun SJ, Lee JB, et al (2009). A clinical and epidemiological study of lupus erythematosus at a tertiary referral dermatology clinic in Korea. <i>Lupus</i> , 18(14): 1320-6.
74507	Bajaj DR, Devrajani BR, Matlani BL (2010). Discoid lupus erythematosus: a profile. <i>J Coll Physicians Surg Pak</i> , 20(6): 361-4.
119755	Blakeway EA, Elshimy N, Muinonen-Martin A, et al (2019). Cutaneous lupus associated with pembrolizumab therapy for advanced melanoma: a report of three cases. <i>Melanoma Res</i> , 29(3): 338-41.
119471	Bockle BC, Sepp NT (2015). Smoking is highly associated with discoid lupus erythematosus and lupus erythematosus tumidus: analysis of 405 patients. <i>Lupus</i> , 24(7): 669-74.
74387	Boeckler P, Cosnes A, Hedelin G, et al (2009). Association of cigarette smoking but not alcohol consumption with cutaneous lupus erythematosus. <i>Arch Dermatol</i> , 145(9): 1012-6.
74388	Bourre-Tessier J, Peschken CA, Bernatsky S, et al (2013). Association of smoking with cutaneous manifestations in systemic lupus erythematosus. <i>Arthritis Care Res</i> , 65(8): 1275-80.
45201	Brehon A, Moguelet P, Guegan S, et al (2020). Discoid drug-induced lupus erythematosus induced by antitumor necrosis factor agents is a very rare subtype of cutaneous lupus: Three cases and literature review. <i>Dermatol Ther</i> , 33(3): e13364.
23351	Calabrese G, Licata G, Gambardella A, et al (2020). A case of discoid lupus erythematosus because of palbociclib. <i>J Cutan Pathol</i> , 47(7): 668-70.
119543	Carlesimo M, Pigliacelli F, D'Arino A, et al (2020). Isoradiotopic response of discoid lupus after radiotherapy: A case report and review of the literature. <i>Dermatol Ther</i> , 33(1): e13183.
74380	Cemil BC, Atas H, Canpolat F, et al (2013). Infliximab-induced discoid lupus erythematosus. <i>Lupus</i> , 22(5): 515-8.

119478	Chanprapaph K, Tubtieng I, Pratumchat N, et al (2021). Cutaneous, systemic features and laboratory characteristics of late- versus adult-onset systemic lupus erythematosus in 1006 Thai patients. <i>Lupus</i> , 30(5): 785-94.
122064	Chatzimichail G, Zillikens D, Thaci D (2020). Secukinumab-induced chronic discoid lupus erythematosus. <i>JAAD Case Rep</i> , 6(4): 362-4.
122106	Clarke J (2024). Initial management of discoid lupus erythematosus and subacute cutaneous lupus erythematosus. Retrieved 15 July 2024, from https://www.uptodate.com/contents/initial-management-of-discoid-lupus-erythematosus-and-subacute-cutaneous-lupus-erythematosus
122107	Clarke J (2024). Management of discoid lupus erythematosus and subacute cutaneous lupus erythematosus refractory to anti-malarial therapy. Retrieved 15 July 2024, from https://www.uptodate.com/contents/management-of-discoid-lupus-erythematosus-and-subacute-cutaneous-lupus-erythematosus-refractory-to-antimalarial-therapy
122067	Cohen PR (2020). Discoid lupus erythematosus lesions associated with systemic fluorouracil agents: a case report and review. <i>Cureus</i> , 12(4): e7828.
74031	Eastham AB (2014). Discoid lupus erythematosus. Retrieved 7 September 2015, from http://emedicine.medscape.com/article/1065529-overview
74386	Eastham AB, Vleugels RA (2014). Cutaneous lupus erythematosus. <i>JAMA Dermatol</i> , 150(3): 344.
122069	Elman SA, Joyce C, Braudis K, et al (2020). Creation and validation of classification criteria for discoid lupus erythematosus. <i>JAMA Dermatol</i> , 156(8): 901-6.
88963	Expert Review Panel for Per- and Poly-Fluoroalkyl Substances (PFAS) (2018). PFAS Expert Health Panel - Report to the Minister. Department of Health, Australian Government.
119486	Fayard D, Frances C, Amoura Z, et al (2022). Prevalence and factors associated with long-term remission in cutaneous lupus: A longitudinal cohort study of 141 cases. <i>J Am Acad Dermatol</i> , 87(2): 323-32.
119542	Ferjani HL, Boussaa H, Maatallah K, et al (2022). [Comment] The first case of leflunomide-induced discoid lupus erythematosus. <i>Therapie</i> , 77(4): 487-8.
122108	Fireman EM, Fireman Klein E (2024). Association between silicosis and autoimmune disease. <i>Curr Opin Allergy Clin Immunol</i> , 24(2): 45-50.
122070	Florez-Pollack S, Rizvi SK, Hynan LS, et al (2022). Discoid lesions and smoking history are negative predictors of disease activity remission in cutaneous lupus erythematosus. <i>J Am Acad Dermatol</i> , 87(5): 1135-7.
74383	Foering K, Chang AY, Piette EW, et al (2013). Characterization of clinical photosensitivity in cutaneous lupus erythematosus. <i>J Am Acad Dermatol</i> , 69(2): 205-13.
117000	Freedman JB, Herskovitz I, Maderal AD (2020). [Comment] Chronic cutaneous lupus erythematosus (discoid lupus) induced by palbociclib. <i>Int J Dermatol</i> , 59(6): e216-8.
41486	Fruchter O, Edoute Y (2004). First presentation of systemic lupus erythematosus following ultraviolet radiation exposure in an artificial tanning device. <i>Rheumatology</i> , 44(4): 558-9.
41532	Gallego H, Crutchfield CE 3rd, Lewis EJ, et al (1999). Report of an association between discoid lupus erythematosus and smoking. <i>Cutis</i> , 63(4): 231-4.
119462	Gomez-Quispe H, Elena de Las Heras-Alonso M, Lobato-Berezo A, et al (2021). Trichoscopic findings of discoid lupus erythematosus alopecia: A cross-sectional study. <i>J Am Acad Dermatol</i> , 84(3): 804-6.

74434	Gronhagen CM, Nyberg F (2014). Cutaneous lupus erythematosus: an update. <i>Indian Dermatol Online J</i> , 5(1): 7-13.
119736	Guettrot-Imbert G, Morel N, Le Guern V, et al (2016). Pregnancy and contraception in systemic and cutaneous lupus erythematosus. <i>Ann Dermatol Venereol</i> , 143(10): 590-600.
119290	Hawat T, Ballouz S, Megarbane H, et al (2022). Pediatric discoid lupus erythematosus: Short report. <i>Dermatol Ther</i> , 35(1): e15170.
119178	Heymann WR (2022). The criteria-dependent risk of systemic lupus erythematosus developing in patients with discoid lupus erythematosus. <i>J Am Acad Dermatol</i> , 87(3): 539-40.
122071	Hile GA, Kahlenberg JM (2021). Immunopathogenesis of skin injury in systemic lupus erythematosus. <i>Curr Opin Rheumatol</i> , 33(2): 173-80.
119606	Hirbod T, Altamura D, Arkoumani E, et al (2017). Discoid lupus erythematosus occurring in an area previously affected by herpes zoster virus: Wolf's isotopic reaction? <i>Eur J Dermatol</i> , 27(2): 186-7.
119745	Hsieh CY, Tsai TF (2022). Aggravation of discoid lupus erythematosus in a patient with psoriasis and psoriatic arthritis during treatment of secukinumab: A case report and review of literature. <i>Lupus</i> , 31(7): 891-4.
119822	Jalenques I, Rondepierre F, Massoubre C, et al (2016). High prevalence of psychiatric disorders in patients with skin-restricted lupus: a case-control study. <i>Br J Dermatol</i> , 174(5): 1051-60.
119487	Jennings T, Ahmed S, Aphale A, et al (2019). Intravenous immunoglobulin G use in patients with chronic inflammatory demyelinating polyneuropathy: An uncommon cause of drug-induced discoid lupus erythematosus. <i>Australas J Dermatol</i> , 60(3): e208-10.
119481	Ji YZ, Mei XL, Wei FL, et al (2020). A secondary discoid lupus erythematosus induced by scald of edible oil: An illustration of Koebner phenomenon. <i>J Cosmet Dermatol</i> , 19(7): 1699-701.
122072	Kannambal K, Tharini GK (2017). A screening study on dermatoses in pregnancy. <i>J Clin Diagn Res</i> , 11(5): WC01-5.
74384	Kim A, Chong BF (2013). Photosensitivity in cutaneous lupus erythematosus. <i>Photodermatol Photoimmunol Photomed</i> , 29(1): 4-11.
51608	Klein LR (1995). Photoexacerbation of cutaneous lupus erythematosus due to ultraviolet A emissions from a photocopier. <i>Arthritis Rheum</i> , 38(8): 1152-6.
122073	Kluger N, Andraud M, Lartigau-Roussin C, et al (2021). The Koebner phenomenon on tattoos and piercings in a patient with cutaneous lupus: a case report and review of the literature. <i>Acta Dermatovenerol Alp Pannonica Adriat</i> , 30(1): 43-6.
122110	Koskenmies S, Jarvinen TM, Onkamo P, et al (2008). Clinical and laboratory characteristics of Finnish lupus erythematosus patients with cutaneous manifestations. <i>Lupus</i> , 17(4): 337-47. [Abstract]
74029	Kuhn A, Landmann A (2014). The classification and diagnosis of cutaneous lupus erythematosus. <i>J Autoimmun</i> , 48-49: 14-9.
23771	Kus KJ, LaChance AH, Vleugels RA (2021). Recognition and management of cutaneous connective tissue diseases. <i>Med Clin North Am</i> , 105(4): 757-82.
103040	Lazarevic N, Smurthwaite K, Trevenar S, et al (2021). PFAS Health Study Component Three: Cross-Sectional Survey of Self-Reported Physical and Mental Health Outcomes and Associations with Blood Serum PFAS. Canberra (AU): The Australian National University.
119483	Li Q, Wu H, Liao W, et al (2018). A comprehensive review of immune-mediated dermatopathology in systemic lupus erythematosus. <i>J Autoimmun</i> , 93: 1-15.
74045	Longhi BS, Centeville M, Marini R, et al (2012). Koebner's phenomenon in systemic lupus erythematosus. <i>Rheumatol Int</i> , 32(5): 1403-5.

121195	Lopes Almeida Gomes L, Werth AJ, Thomas P, et al (2024). The impact of hormones in autoimmune cutaneous diseases. <i>J Dermatolog Treat</i> , 35(1): 2312241.
122074	Manjunath J, Mochel M, Nutan F (2022). Nivolumab-induced de novo discoid lupus erythematosus. <i>Case Rep Dermatol</i> , 14(1): 88-92.
122111	Maz MP, Martens JW, Hannoudi A, et al (2022). Recent advances in cutaneous lupus. <i>J Autoimmun</i> , 132: 102865.
41385	Meier CR, Sturkenboom MC, Cohen AS, et al (1998). Postmenopausal estrogen replacement therapy and the risk of developing systemic lupus erythematosus or discoid lupus. <i>J Rheumatol</i> , 25(8): 1515-9.
122114	Merola J (2024). Overview of cutaneous lupus erythematosus. Retrieved 16 July 2024, from https://www.uptodate.com/contents/overview-of-cutaneous-lupus-erythematosus
122113	Merola J (204). Drug induced lupus. Retrieved 15 July 2024, from https://www.uptodate.com/contents/drug-induced-lupus
19467	Micromedex (2024). Adalimumab: Adverse effects. Retrieved 15 May 2024, from https://www.micromedexsolutions.com/
125685	Micromedex (2025). Certolizumab pegol. Retrieved 13 March 2025, from https://www.micromedexsolutions.com/
118169	Micromedex (2024). Etanercept. Adverse effects. Retrieved 15 May 2024, from https://www.micromedexsolutions.com/
122115	Micromedex (2024). Fluorouracil. Adverse effects. Retrieved 17 July 2024, from https://www.micromedexsolutions.com/micromedex2/librarian/PFDefaultActionId/evidencexpert.DoIntegratedSearch?navitem=topHome&isToolPage=true#
118171	Micromedex (2024). Golimumab: Adverse effects. Retrieved 15 May 2024, from https://www.micromedexsolutions.com
122116	Micromedex (2024). Immune globulin. Adverse effects. Retrieved 8 November 2024, from https://www.micromedexsolutions.com/micromedex2/librarian/CS/75BE57/ND_PR/evidencexpert/ND_P/evidencexpert/DUPLICATIONSHIELDSYN C/5DC368/ND_PG/evidencexpert/ND_B/evidencexpert/ND_AppProduct/evidencexpert/ND_T/evidencexpert/PFActionId/evidencexpert.IntermediateToDocumentLink?docId=0693&contentSetId=31&title=IMMUNE+GLOBULIN&servicesTitle=IMMUNE+GLOBULIN#
122117	Micromedex (2024). Infliximab. Adverse effects. Retrieved 12 July 2024, from https://www.micromedexsolutions.com/micromedex2/librarian/CS/7B1DD D/ND_PR/evidencexpert/ND_P/evidencexpert/DUPLICATIONSHIELDSY NC/9A01F9/ND_PG/evidencexpert/ND_B/evidencexpert/ND_AppProduct/evidencexpert/ND_T/evidencexpert/PFActionId/evidencexpert.DoIntegrate dSearch?SearchTerm=Infliximab&fromInterSaltBase=true&UserMdxSearchTerm=%24userMdxSearchTerm&false=null&=null#
122118	Micromedex (2024). Leflunomide. Adverse effects. Retrieved 17 July 2024, from https://www.micromedexsolutions.com/micromedex2/librarian/PFDefaultActionId/evidencexpert.DoIntegratedSearch?navitem=topHome&isToolPage=true#close
121676	Micromedex (2024). Nivolumab. Adverse effects. Retrieved 28 October 2024, from https://www.micromedexsolutions.com/
121678	Micromedex (2024). Pembrolizumab. Adverse effects. Retrieved 28 October 2024, from https://www.micromedexsolutions.com/

122119	Micromedex (2024). Secukinumab. Adverse effects. Retrieved 11 July 2024, from https://www.micromedexsolutions.com/micromedex2/librarian/CS/688CD/ND_PR/evidencexpert/ND_P/evidencexpert/DUPLICATIONSHIELDSYNC/B2DF4A/ND_PG/evidencexpert/ND_B/evidencexpert/ND_AppProduct/evidencexpert/ND_T/evidencexpert/PFActionId/evidencexpert.DoIntegratedSearch?SearchTerm=secukinumab&UserSearchTerm=secukinumab&SearchFilter=filterNone&navitem=searchALL#
41533	Miot HA, Miot LD, Haddad GR (2005). Association between discoid lupus erythematosus and cigarette smoking. <i>Dermatology</i> , 211(2): 118-22.
119464	Mirali S, Mufti A, Lansang RP, et al (2021). Development of chronic cutaneous lupus erythematosus during biologic therapy: A systematic review. <i>J Am Acad Dermatol</i> , 84(3): 835-8.
80673	O'Donovan A, Cohen BE, Seal KH, et al (2015). Elevated risk for autoimmune disorders in Iraq and Afghanistan veterans with posttraumatic stress disorder. <i>Biol Psychiatry</i> , 77(4): 365-74.
51868	Pace AV, Erb N, Kitas GD (2001). [Comment] Sunlight-induced recurrent acute confusion as the initial presentation of systemic lupus erythematosus. <i>Rheumatology</i> , 40(1): 108-9.
119485	Patel J, Borucki R, Werth VP (2020). An update on the pathogenesis of cutaneous lupus erythematosus and its role in clinical practice. <i>Curr Rheumatol Rep</i> , 22(10): 69.
119289	Petersen MP, Moller S, Bygum A, et al (2018). Epidemiology of cutaneous lupus erythematosus and the associated risk of systemic lupus erythematosus: a nationwide cohort study in Denmark. <i>Lupus</i> , 27(9): 1424-30.
41384	Petri M, Meier CR (1999). [Comment] Postmenopausal estrogen replacement therapy and risk of developing systemic lupus erythematosus or discoid lupus. <i>J Rheumatol</i> , 26(3): 752.
74036	Rojas-Villarraga A, Torres-Gonzalez JV, Ruiz-Sternberg AM (2014). Safety of hormone replacement therapy and oral contraceptives in systemic lupus erythematosus: a systematic review and meta-analysis. <i>PLoS One</i> , 9(8): e104303.
119469	Rua-Figueroa I, Erasquin C, Rua-Figueroa C, et al (2020). Tobacco smoking is an independent factor associated with retinal damage in systemic lupus erythematosus: a cross-sectional and retrospective study. <i>Rheumatol Int</i> , 40(3): 367-74.
74044	Ruocco E, Brunetti G, Sangiuliano S, et al (2013). Discoid lupus erythematosus at a site of previous injury. <i>Australas J Dermatol</i> , 54(1): e16-8.
42012	Sanchez-Guerrero J, Liang MH, Karlson EW, et al (1995). Postmenopausal estrogen therapy and the risk for developing systemic lupus erythematosus. <i>Ann Intern Med</i> , 122(6): 430-3.
50168	Sanders CJ, Van Weelden H, Kazzaz GA, et al (2003). Photosensitivity in patients with lupus erythematosus: a clinical and photobiological study of 100 patients using a prolonged phototest protocol. <i>Br J Dermatol</i> , 149(1): 131-7.
49436	Schmidt E, Tony HP, Brocker EB, et al (2007). Sun-induced life-threatening lupus nephritis. <i>Ann N Y Acad Sci</i> , 1108: 35-40.
122123	Senderey E, Patel S (2017). Discoid lupus erythematosus: when a superficial injury is a red herring of underlying disease. <i>BMJ Case Rep</i> , 2017: bcr2017222235.
122125	Shakhbazova A, Marsch AF (2019). Systemic 5-fluorouracil induced lupus erythematosus: a review of the literature. <i>Dermatol Online J</i> , 25(11): 13030/qt3nw0p7hn.

74382	Shimaoka Y, Hatamochi A, Hamasaki Y, et al (2008). Discoid lupus erythematosus exacerbated by contact dermatitis caused by use of squaric acid dibutylester for topical immunotherapy in a patient with alopecia areata. <i>J Dermatol</i> , 35(3): 151-3.
119463	Silvestri M, Cristaudo A, Morrone A, et al (2021). Emerging skin toxicities in patients with Breast cancer treated with new cyclin-dependent kinase 4/6 inhibitors: a systematic review. <i>Drug Saf</i> , 44(7): 725-32.
50478	Stern RS, Docken W (1986). [Comment] An exacerbation of SLE after visiting a tanning salon. <i>JAMA</i> , 255(22): 3120.
119605	Szczech J, Samotij D, Werth VP, et al (2017). Trigger factors of cutaneous lupus erythematosus: a review of current literature. <i>Lupus</i> , 26(8): 791-807.
122127	Vale EC, Garcia LC (2023). Cutaneous lupus erythematosus: a review of etiopathogenic, clinical, diagnostic and therapeutic aspects. <i>An Bras Dermatol</i> , 98(3): 355-72.
119480	van der Molen RG, Hamann D, Jacobs JF, et al (2015). Anti-SSA antibodies are present in immunoglobulin preparations. <i>Transfusion</i> , 55(4): 832-7.
1230	Veasey EC, Schadt CR (2019). Photosensitivity in cutaneous lupus. <i>JAMA Dermatol</i> , 155(12): 1417.
122128	Vitzthum von Eckstaedt H, Singh A, Reid P, et al (2024). Immune checkpoint inhibitors and lupus erythematosus. <i>Pharmaceuticals (Basel)</i> , 17(2): 252.
119482	Wang RF, Maher M, Chung C, et al (2019). Koebner phenomenon of discoid lupus erythematosus on old tattoos. <i>Lupus</i> , 28(2): 241-3.
119470	Warnakulasuriya S (2018). Clinical features and presentation of oral potentially malignant disorders. <i>Oral Surg Oral Med Oral Pathol Oral Radiol</i> , 125(6): 582-90.
119484	Wen PF, Wang S (2015). Discoid lupus erythematosus-associated Koebnerization at the site of healed herpes zoster. <i>Australas J Dermatol</i> , 56(4): 313-4.
74385	Williams VL, Cohen PR (2011). TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists. <i>Int J Dermatol</i> , 50(5): 619-25.
122129	Yamaga R, Tezuka K, Sugawara S, et al (2018). S-1 induced discoid lupus erythematosus-like lesions and long-term complete response for para-aortic lymph node recurrence of pancreatic ductal adenocarcinoma: a case report. <i>Surg Case Rep</i> , 4(1): 52.
122131	Yavuz GO, Yavuz IH, Bayram I, et al (2019). Clinic experience in discoid lupus erythematosus: a retrospective study of 132 cases. <i>Postepy Dermatol Alergol</i> , 36(6): 739-43.
74862	Yoshimasu T, Hiroi A, Uede K, et al (2001). Discoid lupus erythematosus (DLE)-like lesion induced by uracil-tegafur (UFT). <i>Eur J Dermatol</i> , 11(1): 54-7.
119248	Yu Y, Jin H, Zhou S, et al (2023). The differential panorama of clinical features of lupus erythematosus patients with different onset ages: a cross-sectional multicenter study from China. <i>Clin Rheumatol</i> , 42(9): 2353-67.